The drug "Cernilton". Reviews

The drug "Cernilton" (analogue of the drug is not registered) is available in the form of biconvex, round tablets. Color light or pale yellow. Tablets have small, darker color impregnations. The agent "Cernilton" has a specific smell. The preparation has a plant basis.

Means of "Cernilton". Instructions

The drug is used for benign prostatic hyperplasia .

The drug has anti-edematous and anti-inflammatory effect, actively promotes the regulation of metabolic (metabolic) processes.

The drug "Cernilton" (reviews and comments of experts confirm this) has a number of useful properties, due to which the synthesis of inflammatory mediators in the cycle of arachidonic acid: leukotrienes and prostaglandins is slowed down.

As a result, there is a decrease in edema and inflammation in the prostate tissue.

The agent "Cernilton" (patient reviews indicate this) helps to reduce the intensity of the pain syndrome.

The drug has a miorelaksiruyuschee effect. This helps to relax the elements of smooth muscles in the back of the urethra, which, in turn, improves urination.

The drug helps to reduce the volume of the prostate, blocks alpha-1-adrenoreceptors of smooth muscle components in the urethra, has anti-androgenic activity. The drug "Cernilton" (patients' reviews also confirm this) contribute to the normalization of erectile function.

The agent is shown in the complex therapy for chronic and acute prostatitis, prostate hyperplasia of benign nature, including in combination with prostatitis.

The drug "Cernilton" (doctors' reviews are unambiguous in that) is not allowed to be used if there is hypersensitivity to the components.

The remedy is recommended for ingestion before meals (usually half an hour). Tablets are washed down with water in small amounts.

With an acute prostatitis, usually three times a day, four tablets are administered. The duration of therapy is determined by the doctor. As a rule, the duration of admission is three months.

With prostatitis chronic course recommended by the tablet three to four times a day. The duration of therapy can be from three to six months.

With benign prostatic hyperplasia, three tablets a day are given on two tablets. The duration of therapy is usually six to twelve weeks, but if necessary, it can be increased to six months.

When taking the drug should be remembered that hypersensitivity to the components may manifest nausea, vomiting, allergies.

In clinical practice, no cases of overdose have been documented. There are also no clinically relevant information about the interaction of the drug with other medicines.

The administration of the agent for chronic prostatitis of bacterial nature is allowed only in combination with antibacterial agents. Therapy in this case should be supervised by a specialist.